Dendritic cells derived from pluripotent stem cells:Potential of large scale production

作     者：Yan Li Meimei Liu Shang-Tian Yang 

作者机构：Department of Chemical and Biomedical EngineeringFlorida Agricultural and Mechanical University-Florida State University College of EngineeringFlorida State University William G. Lowrie Department of Chemical and Biomolecular EngineeringThe Ohio State University 

出 版 物：《World Journal of Stem Cells》 (世界干细胞杂志（英文版）（电子版）)

年 卷 期：2014年第6卷第1期

页      面：1-10页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by In part by Florida State University start up fund Florida State University Research Foundation GAP award the partial support from National Science Foundation,No.1342192 

主　　题：Pluripotent stem cells Dendritic cells Bioreactor Hematopoietic differentiation Large scale production 

摘      要：Human pluripotent stem cells(hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, are promising sources for hematopoietic cells due to their unlimited growth capacity and the pluripotency. Dendritic cells(DCs), the unique immune cells in the hematopoietic system, can be loaded with tumor specific antigen and used as vaccine for cancer immunotherapy. While autologous DCs from peripheral blood are limited in cell number, hPSC-derived DCs provide a novel alternative cell source which has the potential for large scale production. This review summarizes recent advances in differentiating hPSCs to DCs through the intermediate stage of hematopoietic stem cells. Step-wise growth factor induction has been used to derive DCs from hPSCs either in suspension cultureof embryoid bodies(EBs) or in co-culture with stromal cells. To fulfill the clinical potential of the DCs derived from hPSCs, the bioprocess needs to be scaled up to produce a large number of cells economically under tight quality control. This requires the development of novel bioreactor systems combining guided EB-based differentiation with engineered culture environment. Hence, recent progress in using bioreactors for hPSC lineage-specific differentiation is reviewed. In particular, the potential scale up strategies for the multistage DC differentiation and the effect of shear stress on hPSC differentiation in bioreactors are discussed in detail.